Healthcare
CochLear Ltd.(CHEOY)
Live Price
Offline$39.72
-0.65% today
1Y Change
-61.33%
Window
Jun 25, 2025 β Jun 16, 2026
- Market Cap
- $6.51B
- Revenue Growth
- +4.8%
- EPS Growth
- +9.4%
- Dividend Yield
- 4.3%
Coverage: 245 bars Β· Jun 25, 2025 β Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CochLear Ltd. (CHEOY) is a Healthcare stock with a market cap of $6.51B and listed on OTC. The stock last traded around $39.72 and down 61.3% across the available one-year price window (Jun 25, 2025 β Jun 16, 2026). Baseline metrics include revenue growth of +4.8%, EPS growth of +9.4%, a dividend yield of 4.3%. What stands out right now is revenue +4.8%, EPS +9.4%, free cash flow -54.8% with operating margin 20.0% and ROIC 15.7%. The dividend matters to the case here, with a current yield around 4.3%. Valuation is more restrained than many high-expectation growth names at P/E 18.8 and price/sales 2.8. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines CHEOY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.8% vs +7.6% peer median
Operating Margin
Near sector median
+20.0% vs +19.4% peer median
P/E
Below sector median
18.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +4.8% and EPS at +9.4%, with operating margin around 20.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.3%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 11, 2026 | β | -4.5% | -22.3% | -30.0% |
2025 Aug 18, 2025 | β | -0.1% | +1.9% | +6.1% |
2025 Feb 13, 2025 | β | +0.3% | +1.1% | +4.5% |
Benchmark Edge
CHEOY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CHEOY
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CHEOY Max Drawdown
-69.34%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CHEOY and SPY.
Company Overview
CochLear Ltd.
OTC
Cochlear Ltd Unsponsored ADR represents an American Depositary Receipt for Cochlear Limited, an Australian company specializing in implantable hearing solutions. These ADRs allow U.S. investors to engage in foreign stocks without the complexities of direct overseas investments. Cochlear Ltd is renowned for its pioneering technological advancements in the field of audiology, primarily focusing on cochlear implants that deliver cochlear and acoustic solutions to individuals with severe hearing loss. Operating across healthcare and medical technology sectors, the company plays a crucial role in improving quality of life through auditory rehabilitation. The unsponsored nature of the ADR indicates that it may be managed by several depositary banks, rather than being issued in coordination with the underlying company. This provides investors with the opportunity to participate in Cochlearβs growth and innovations, reflecting the significant market demands in healthcare solutions and aging demographics. Cochlear Ltd ADRs thereby serve as a gateway for exposure to dynamic developments within the medical device industry and Australia's burgeoning healthcare market.
- Leadership
- Mr. Diggory William Howitt BE (Hons), MBA
- Employees
- 5.5k
- Street Address
- 1 University Avenue, Macquarie University
- Mailing
- Sydney, NSW, 2109
- Region
- Sydney, NSW, Australia
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.8
- EV/EBITDA
- 11.9
- Price/Sales
- 2.8
- Price/Book
- 3.4
Growth
- Revenue
- +4.8%
- EPS
- +9.4%
- Free Cash Flow
- -54.8%
Profitability
- Gross Margin
- 73.0%
- Operating Margin
- 20.0%
- Net Margin
- 14.6%
- ROE
- 17.8%
- ROIC
- 15.7%
Balance Sheet
- Debt/Equity
- 0.22
- Current Ratio
- 2.46
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.